| [1] |
Roth BJ, Krilov L, Adams S, et al. Clinical cancer advances 2012: annual report on progress against cancer from the American Society of Clinical Oncology[J]. J Clin Oncol,2013,31(1): 131-161.
|
| [2] |
Verma S, Miles D, Gianni L,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med,2012,367(19): 1783-1791.
|
| [3] |
Baselga J,Cortés J,Kim SB,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med,2012,366(2): 109-119.
|
| [4] |
Tsakonas E,Fitzgerald AA,Fitzcharles MA,et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study[J]. J Rheumatol,2000,27(3): 623-629.
|
| [5] |
O'Regan R, Hawk NN. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy[J]. Expert Opin Ther Targets,2011,15(7): 859-872.
|
| [6] |
Howell SJ. Advances in the treatment of luminal breast cancer[J]. Curr Opin Obstet Gynecol,2013,25(1): 49-54.
|
| [7] |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor positive advanced breast cancer[J]. N Engl J Med,2012,366(6): 520-529.
|
| [8] |
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al.Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial[J]. J Clin Oncol,2012,30(1): 11-18.
|